Elicera Therapeutics AB (publ) (STO: ELIC)

Market Cap	61.41M
Revenue (ttm)	4.29M
Net Income (ttm)	-18.26M
Shares Out	35.09M
EPS (ttm)	-0.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	171,539
Open	1.720
Previous Close	1.720
Day's Range	1.720 - 1.850
52-Week Range	0.852 - 5.680
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 29, 2024

About Elicera Therapeutics AB

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 2
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ELIC

Financial Performance

In 2023, Elicera Therapeutics AB's revenue was 11.23 million, an increase of 777.23% compared to the previous year's 1.28 million. Losses were -16.40 million, -15.64% less than in 2022.